<div id="readability-page-1"><p>Krystal Biotech (NASDAQ:KRYS - Get Free Report) announced its earnings results on Monday. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.38, FiscalAI reports. The business had revenue of $116.36 million during the quarter, compared to analysts' expectations of $112.11 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.</p><div><p><span></span><span>Get <strong>Krystal Biotech</strong> alerts:</span></p></div><h2>Krystal Biotech Stock Performance</h2><ul><li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li></ul><p>Shares of NASDAQ:KRYS opened at $266.04 on Monday. The firm has a 50 day simple moving average of $261.72 and a 200 day simple moving average of $246.50. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $298.30. The company has a market cap of $7.83 billion, a PE ratio of 38.84 and a beta of 0.50. </p><h2>Insider Activity</h2><p>In other news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the transaction, the chief accounting officer owned 22,366 shares in the company, valued at approximately $5,985,141.60. The trade was a 3.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel Janney sold 11,803 shares of the company's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $275.59, for a total value of $3,252,788.77. Following the transaction, the director directly owned 73,293 shares in the company, valued at $20,198,817.87. The trade was a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 129,164 shares of company stock valued at $34,538,578 in the last 90 days. Company insiders own  13.10% of the company's stock. </p><h2>Institutional Investors Weigh In On Krystal Biotech</h2><ul><li>Krystal Clear: Krystal Biotech Clears Resistance in Good Volume</li></ul><p>A number of institutional investors have recently bought and sold shares of the business. Greenline Wealth Management LLC purchased a new position in  Krystal Biotech during the 4th quarter valued at about $34,000.  Danske Bank A S purchased a new stake in shares of  Krystal Biotech in the third quarter worth approximately $35,000.  UMB Bank n.a. boosted its holdings in shares of  Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company's stock worth $36,000 after purchasing an additional 37 shares during the period.  Global Retirement Partners LLC boosted its holdings in shares of  Krystal Biotech by 788.9% during the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company's stock worth $39,000 after purchasing an additional 142 shares during the period.  Finally, Osaic Holdings Inc. grew its position in  Krystal Biotech by 41.4% during the second quarter. Osaic Holdings Inc. now owns 393 shares of the company's stock valued at $54,000 after purchasing an additional 115 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several equities research analysts have commented on KRYS shares. Guggenheim boosted their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, February 25th. Weiss Ratings raised shares of Krystal Biotech from a &#34;hold (c+)&#34; rating to a &#34;buy (b-)&#34; rating in a research note on Thursday, April 9th. The Goldman Sachs Group boosted their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, January 30th. Wolfe Research began coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They set a &#34;peer perform&#34; rating for the company. Finally, HC Wainwright  restated a &#34;buy&#34; rating and set a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. Nine investment analysts have rated the stock with a Buy rating and two have assigned  a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $326.25.</p><p><b>View Our Latest Stock Analysis on KRYS</b></p><h2>Krystal Biotech Company Profile</h2> (Get Free Report)<p>Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.  </p><p>The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Krystal Biotech</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JZUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JZUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Krystal Biotech Right Now?</h2><p>Before you consider Krystal Biotech, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.</p><p>While Krystal Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

KRYS

IBBQ

<p>Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.83 EPS, exceeding expectations by $0.38. The company generated revenue of $116.36 million, surpassing the consensus estimate of $112.11 million. With a net margin of 52.64% and a return on equity of 18.69%, Krystal Biotech's stock performance remains strong, with a market cap of $7.83 billion. Recent insider sales and institutional investments indicate active trading, while analysts maintain a positive outlook with multiple buy ratings and a consensus price target of $326.25.</p>

Market Beat

Krystal Biotech

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Danske Bank

UMB Financial

Goldman Sachs

GS Hldg R

Krystal Biotech (NASDAQ:KRYS) Releases Quarterly Earnings Results, Beats Expectations By $0.38 EPS